Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...

The increasing prevalence of kidney failure and end-stage renal disease, along with a growing incidence of risk factors like ...

USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, Feb. 11, 2025 /PRNewswire/ -- USA News Group News Commentary - Weeks after the monumental ...

Beyond Stargate's big players, a growing number of innovators have been revolutionizing healthcare by making recent ...

A new study led by researchers from Peking University, published in Health Data Science, reveals a sharp rise in the burden of early-onset type 2 diabetes (T2D) among adolescents and young adults ...

WASHINGTON — Patients who use smartphone apps to manage their diabetes could face serious health problems if they miss notifications needed to control their blood sugar, U.S. health officials ...

Analysing the top 10 tech company logos, we can understand the art and science behind creating visual identities that stand out from the crowd. Most people scroll past logos like they're invisible.

Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or ...

To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, ...

Basel, 04 February 2025 - Roche (SIX: RO, ROG ... macular edema (DME), a leading cause of vision loss in adults with diabetes, affecting more than 29 million adults worldwide.

Basel, 04 February 2025 - Roche ... with diabetes, affecting more than 29 million adults worldwide. 1-3 Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with DME ...